Cerdulatinib

DB15499InvestigationalSmall molecule

Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK1, Non-receptor tyrosine-protein kinase TYK2, and Tyrosine-protein kinase JAK3
Curator reviewed
Formula / weight: C₂₀H₂₇N₇O₃S · 445.54 g/mol (avg)
Also known as: 4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide · 5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-
Code names: PRT-062070

Resolves to

Compound

UNIID1LXQ45S1OCAS1198300-79-6ChEMBLCHEMBL4116008

Structure

InChIKeyBGLPECHZZQDNCD-UHFFFAOYSA-NSMILESCCS(=O)(=O)N1CCN(CC1)C1=CC=C(NC2=NC=C(C(N)=O)C(NC3CC3)=N2)C=C1

Targets

P23458JAK1P29597TYK2P52333JAK3P43405SYKO60674JAK2

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

20+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cerdulatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account